Clinical trial
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
NCT00126191 · Dana-Farber Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00126191 |
|---|---|
| Title | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma |
| Official title | Phase II Study of Intensive Chemotherapy and Rituximab in Burkitt Lymphoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Brigham and Women's Hospital |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Methotrexate, Leucovorin, Ifosfamide, Etoposide, Cytarabine, Mesna |
| Enrollment | 10 |
| Start date | Jul 1, 2005 |
| Primary completion | Dec 1, 2009 |
| Completion | Jun 1, 2011 |
| First posted | Aug 3, 2005 |
| Last update posted | May 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: